Certified by Founder
Lodge
NeuroSense Therapeutics
start up
United States
- Cambridge, Massachusetts
- 09/12/2021
- Unknown
- $12,000,000
Advancing research, development and therapy for ALS and additional CNS indications.
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) is a clinical stage Biotech company focusing on the development of a ground-breaking treatment for ALS patients, as well as other neurodegenerative diseases.
Currently in preparations towards a Phase IIb in ALS patients in USA and Israel.
- Industry Biotechnology Research
- Website http://www.neurosense-tx.com/
- LinkedIn https://www.linkedin.com/company/neurosense-therapeutics/about/
Related People
Alon Ben-NoonCo Founder
Israel -
Herzliyya, Tel Aviv
Life Sciences Executive ; Leading NeuroSense Therapeutics, a Biotech startup which accelerates research, development and therapy for ALS (Amyotrophic Lateral Sclerosis) and additional Neurodegenerative diseases.
LinkedIn
https://www.linkedin.com/in/alonbn/
Ethermed | $8,500,000 | (Apr 17, 2026)
Joyful Health | $17,000,000 | (Apr 17, 2026)
Worki.ai | $2,750,000 | (Apr 17, 2026)
Balerion AI | $6,000,000 | (Apr 17, 2026)
Beeline Medicines | $300,000,000 | (Apr 17, 2026)
Expo | $45,000,000 | (Apr 17, 2026)
Sepion Technologies | $10,000,000 | (Apr 17, 2026)
Lua AI (YC F25) | $5,800,000 | (Apr 17, 2026)
Nas.com | $27,000,000 | (Apr 17, 2026)
Resolv | $1,000,000 | (Apr 17, 2026)
Solidroad | $25,000,000 | (Apr 17, 2026)
Parasail | $32,000,000 | (Apr 16, 2026)